Completing data — refresh the page later to see the latest
154039-60-8CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)COCSMOTCMPXTDND-OUAUKWLOSA-N154039-60-8DTXSID20165524CHEMBL279785CHEBI:50662Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
UsesAntineoplastic (matrix metalloproteinase inhibitor).
UsesMarimastat acts as a matrix metalloproteinase inhibitor in the treatment of various cancers, and pathological occurrences such as arthritis and atherosclerosis.
UsesMarimastat has been used as an inhibitor of:metalloproteinase 2/9 (MMP2/9), to study its effects on exercise-mediated interleukin-6 (IL-6) release in micemetalloproteinase, to determine protease activity in Pseudomonas aeruginosa culturesmetalloproteinase 10 (MMP10), to study its effect on monoclonal antibody H3 binding to MMP10
General DescriptionAn orally active peptidyl hydroxamate-based broad-spectrum MMP inhibitor (IC50 in nM = 5, 6, 200, 20, 2, 1.8 and 3.8 for MMP-1, -2, -3, -7, -8, -14 and TACE, respectively) that targets both the substrate binding site and the active-site Zn2+. Marimastate is widely used in studying the involvement of MMPs in various cellular and pathological processes both in vitro and in vivo.
No reaction records under the current filter.
Loading…
DefinitionChEBI: Marimastat is a secondary carboxamide resulting from the foraml condensation of the carboxy group of (2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the alpha-amino group of N,3-dimethyl-L-valinamide. It has a role as an antineoplastic agent and a matrix metalloproteinase inhibitor. It is a secondary carboxamide and a hydroxamic acid.